maxacalcitol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
Vitamin D analogues/derivatives	1638	103909-75-7

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

22-oxacalcitriol
maxacalcitol
oxarol

Molecular weight: 418.62
Formula: C26H42O4
CLOGP: 4.17
LIPINSKI: 0
HAC: 4
HDO: 3
TPSA: 69.92
ALOGS: -4.45
ROTB: 6

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,CDK5,EIF2AK3,GRK2,ITK,PDK1,PDK2,PDK4	8
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Shunt stenosis	480.16	53.26	55	503	504	90627385
Shunt occlusion	277.64	53.26	35	523	740	90627149
Peripheral arterial occlusive disease	66.80	53.26	13	545	4608	90623281
Cardiac failure	59.31	53.26	23	535	109473	90518416

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Shunt stenosis	474.65	47.97	65	852	712	42619706
Shunt occlusion	245.92	47.97	38	879	989	42619429
Peripheral arterial occlusive disease	93.63	47.97	23	894	6815	42613603

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Shunt stenosis	916.54	42.58	120	1602	1296	110586281
Shunt occlusion	497.41	42.58	72	1650	1665	110585912
Peripheral arterial occlusive disease	163.17	42.58	36	1686	9244	110578333
Angina unstable	85.41	42.58	24	1698	16408	110571169
Cardiac failure	76.02	42.58	43	1679	187583	110399994
Shunt infection	59.56	42.58	9	1713	276	110587301
Cerebral infarction	58.38	42.58	24	1698	51814	110535763
Hypocalcaemia	53.02	42.58	24	1698	65342	110522235
Shunt aneurysm	48.62	42.58	6	1716	37	110587540
Aortic valve stenosis	45.73	42.58	12	1710	6338	110581239

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D016588	Anticarcinogenic Agents
MeSH PA	D020011	Protective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Pustular psoriasis	indication	200973000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.7	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Vitamin D3 receptor	Nuclear hormone receptor	P11473	VDR_HUMAN		EC50	9.07		CHEMBL
Vitamin D3 receptor	Transcription factor		VDR_RAT	AGONIST	EC50	8.21		IUPHAR

External reference:

ID	Source
D01098	KEGG_DRUG
C0043872	UMLSCUI
CHEBI:31801	CHEBI
MCZ	PDB_CHEM_ID
CHEMBL333950	ChEMBL_ID
DB06272	DRUGBANK_ID
C051883	MESH_SUPPLEMENTAL_RECORD_UI
6398761	PUBCHEM_CID
2784	IUPHAR_LIGAND_ID
7438	INN_ID
N2UJM5NBF6	UNII
N2UJM5NBF6	INXIGHT DRUGS

Pharmaceutical products:

None